The role of IL-1 in the pathogenesis of heart disease.

The role of IL-1 in the pathogenesis of heart disease.
复制标题

DOI:
10.1007/s00005-009-0024-y
复制
发表时间:
2009-05
影响因子:
3.2
通讯作者:
Frangogiannis, Nikolaos G.
Frangogiannis, Nikolaos G.
中科院分区:
医学4区
文献类型:
--
作者:
Bujak, Marcin;Frangogiannis, Nikolaos G.

文献摘要

参考文献

被引文献

相似文献

IL-1由两种不同的配体(IL-1α和IL-1β)组成,它们具有不可区分的生物活性,通过IL-1 I型受体(IL-1RI)发出信号。天然存在的IL-1受体拮抗剂(IL-1Ra)与IL-1RI结合而不启动信号转导并阻止IL-1信号传导,竞争性地抑制IL-1介导的反应。新出现的证据表明,IL-1激动剂和拮抗剂之间的平衡在多种心血管疾病中起着重要作用。IL-1可能通过促进动脉粥样硬化病变的形成、增强血管炎症和触发斑块不稳定而在动脉粥样硬化血栓性疾病中发挥作用。心肌梗死后,IL-1通过增强基质金属蛋白酶的表达,调控炎症反应并参与不良重构的发展。IL-1信号也可能通过抑制心脏收缩、促进心肌肥大和诱导心肌细胞凋亡而成为心力衰竭发病机制的重要介质。本综述总结了目前可用的数据,显示了IL-1信号在心脏病中的重要作用,并提出了IL-1抑制剂(如anakinra,一种非糖基化重组人IL-1Ra)可能在临床上对某些心血管疾病患者有用的可能性。
IL-1 consists of two distinct ligands (IL-1α and IL-1β) with indistinguishable biological activities that signal through the IL-1 type I receptor (IL-1RI). A naturally occurring IL-1 receptor antagonist (IL-1Ra) binds to IL-1RI without initiating signal transduction and prevents IL-1 signaling, competitively inhibiting IL-1-mediated responses. Emerging evidence suggests that the balance between IL-1 agonists and antagonists plays an essential role in a variety of cardiovascular conditions. IL-1 may play a role in atherothrombotic disease by promoting formation of atheromatous lesions, enhancing vascular inflammation, and triggering plaque destabilization. Following myocardial infarction, IL-1 critically regulates the inflammatory response and is involved in the development of adverse remodeling by enhancing expression of matrix metalloproteinases. IL-1 signaling may also be an essential mediator in the pathogenesis of heart failure by suppressing cardiac contractility, promoting myocardial hypertrophy and inducing cardiomyocyte apoptosis. The present review summarizes current available data showing the significant role of IL-1 signaling in heart disease and raising the possibility that IL-1 inhibitors (such as anakinra, a nonglycosylated recombinant human IL-1Ra) may be clinically useful agents in patients with certain cardiovascular conditions.
DOI: 10.1186/1745-6215-9-8
发表时间: 2008-02-25
期刊: TRIALS
影响因子: 2.5
作者:
Crossman, David C.;Morton, Allison C.;Gunn, Julian P.;Greenwood, John P.;Hall, Alistair S.;Fox, Keith Aa;Lucking, Andrew J.;Flather, Marcus D.;Lees, Belinda;Foley, Claire E.
通讯作者: Foley, Claire E.
DOI: 10.1111/j.1365-2249.2007.03441.x
发表时间: 2007-08-01
影响因子: 4.6
作者:
Barksby, H. E.;Lea, S. R.;Taylor, J. J.
通讯作者: Taylor, J. J.
DOI: 10.1086/513856
发表时间: 1999-03-01
影响因子: 6.4
作者:
Dinarello, CA
通讯作者: Dinarello, CA
DOI: 10.1073/pnas.87.17.6487
发表时间: 1990-09-01
影响因子: 11.1
作者:
COZZOLINO, F;TORCIA, M;STERN, DM
通讯作者: STERN, DM
DOI: 10.1016/j.jacc.2008.01.011
发表时间: 2008-04-08
影响因子: 24
作者:
Bujak, Marcin;Kweon, Hyuk Jung;Frangogiannis, Nikolaos G.
通讯作者: Frangogiannis, Nikolaos G.